SCHEMBL933054

SCHEMBL933054

CN1CCN(c2ccc3nc(-c4ccc(N)c(N)c4)[nH]c3c2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
TOP1 P11387 3/20 0.71
TOP2A P11388 3/20 0.71
HPGD P15428 1/20 0.71
HSD17B10 Q99714 1/20 0.71
TERT O14746 4/20 0.67
MEN1 O00255 2/20 0.65
MAPT P10636 2/20 0.65
BLM P54132 2/20 0.65
KMT2A Q03164 2/20 0.65
SLCO2B1 O94956 1/20 0.65
GLA P06280 1/20 0.65
RECQL P46063 1/20 0.65
BCL2L1 Q07817 1/20 0.65
SLCO1B3 Q9NPD5 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
SLCO1B1 Q9Y6L6 1/20 0.65
KDM4E B2RXH2 2/20 0.64
NPC1 O15118 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1551571 0.91 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14669385 0.89 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14906738 0.88 NPBWR1 (0.58) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14906542 0.87 CBFB (0.58) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14892811 0.86 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14656343 0.85 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL24233364 0.85 MAPT (0.63) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14399402 0.84 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL18595033 0.84 SMN1; SMN2 (0.77) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14906587 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475443-B1 METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS LIFE TECHNOLOGIES CORP (US) 2025-02-12 EP disclosed
WO-2022021981-A1 DI-(BENZIMIDAZOLE)-1, 2, 3-TRIAZOLE DERIVATIVE AND PREPARATION THEREFOR AND USE THEREOF 中南大学湘雅二医院 2022-02-03 WO disclosed
US-20210324198-A1 SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES Life Technologies Corporation 2021-10-21 US disclosed
EP-3833715-A2 SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES Life Technologies Corporation (US) 2021-06-16 EP disclosed
WO-2021105887-A1 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP BIOTECH GMBH (DE) 2021-06-03 WO disclosed
US-20210155657-A1 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP BIOTECH GMBH (DE) 2021-05-27 US disclosed
US-10941435-B2 Methods and compositions for detecting or measuring caspases or apoptosis Life Technologies Corporation (US) 2021-03-09 US disclosed
WO-2020033681-A2 SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES Life Technologies Corporation (US) 2020-02-13 WO disclosed
US-20190309341-A1 METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS Life Technologies Corporation (US) 2019-10-10 US disclosed
EP-3475443-A1 METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS Life Technologies Corporation (US) 2019-05-01 EP disclosed
WO-2017223147-A1 METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS Life Technologies Corporation (US) 2017-12-28 WO disclosed
WO-2011008985-A2 METHODS AND COMPOSITIONS FOR IMPROVED DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2011-01-20 WO disclosed
WO-2007016455-A2 COMPOSITIONS AND METHODS USING AMINOGLYCOSIDES TO BIND DNA AND RNA CLEMSON UNIVERSITY RESEARCH FOUNDATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155657-A1 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE ADAR, SSBP1, POLRMT ALDH1A1 4165/4885SMN1; SMN2 1103/4885TOP1 237/4885
US-10941435-B2 Methods and compositions for detecting or measuring caspases or apoptosis CASP3, CASP5, CASP1 ALDH1A1 4307/4885SMN1; SMN2 3701/4885TOP1 199/4885
US-20210324198-A1 SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES SRI, SI, IK ALDH1A1 1849/4885SMN1; SMN2 2012/4885TOP1 1255/4885
US-20190309341-A1 METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS CASP3, CASP5, CASP7 ALDH1A1 4303/4885SMN1; SMN2 3636/4885TOP1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.